HOOKIPA, Roche form collaboration to develop arenaviral immunotherapy for KRAS-mutated cancers

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing.

OncoHost awarded €2.5M grant from the EIC Transition Programme to advance precision oncology

OncoHost, together with its partners Heidelberg University Hospital, European Institute of Oncology and Virgen Macarena University Hospital, announced on May 15 that the parties have been awarded a €2.5 million grant from the EIC Transition Program of Horizon Europe.

May 16, 2025

Vol.51 No.19

Drugs & Targets

RyboDyn expands strategic cancer immunotherapy collaboration with Moffitt Cancer Center

RyboDyn, Inc. announced on May 15 the expansion of its strategic collaboration with Moffitt Cancer Center, a global leader in cancer care and research.

May 16, 2025

Vol.51 No.19

Clinical

Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Three years ago, researchers from Memorial Sloan Kettering Cancer Center published stunning results: For the 5% of rectal cancer patients whose tumors are mismatch-repair deficient, neoadjuvant dostarlimab-gxly (Jemperli) has the makings of a silver bullet.

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile
Six years later, she is well—and pregnant with her third child

When Kelly Spill was eight months pregnant, she experienced some constipation and noticed blood in her stool. Her OBGYN wasn’t worried.

TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

Immunotherapy has changed the course of blood cancers and melanomas, but is stubbornly ineffective for the treatment of most epithelial solid cancers—the cancers that kill about 90% of the more than 600,000 Americans who die of cancer each year.

April 18, 2025

Vol.51 No.15

By Jacquelyn Cobb

HOOKIPA, Roche form collaboration to develop arenaviral immunotherapy for KRAS-mutated cancers

YOU MAY BE INTERESTED IN

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

OncoHost awarded €2.5M grant from the EIC Transition Programme to advance precision oncology

RyboDyn expands strategic cancer immunotherapy collaboration with Moffitt Cancer Center

Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile
Six years later, she is well—and pregnant with her third child

TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

Renew today!

Subscriber content

Never miss an issue!

Login

HOOKIPA, Roche form collaboration to develop arenaviral immunotherapy for KRAS-mutated cancers

YOU MAY BE INTERESTED IN

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient livesIn a time of uncertainty, “react to the knowns, not the fear”

OncoHost awarded €2.5M grant from the EIC Transition Programme to advance precision oncology

RyboDyn expands strategic cancer immunotherapy collaboration with Moffitt Cancer Center

Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertileSix years later, she is well—and pregnant with her third child

TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

Never miss an issue!

Login

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile
Six years later, she is well—and pregnant with her third child